Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Expert Review of Hematology|December 27, 2016
The current state of adverse event reporting in hemophiliaLize F D van Vulpen, Giorgia Saccullo, Alfonso Iorio, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 4, 2020
Synovitis and synovectomy in haemophiliaLize F D van Vulpen, Sylvia Thomas, Swapnil A Keny, et al.
Expert Review of Hematology|April 6, 2019
An update on the 'danger theory' in inhibitor development in hemophilia ASarah J Schep, Marianne Boes, Roger E G Schutgens, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 9, 2020
[Diagnostics on suspicion of a bleeding disorder]Lize F D van Vulpen, Iris M Wichers, Rolf T Urbanus, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2026
Predicting Recovery After Joint Bleeding in Persons With Bleeding DisordersGijs Aertssen, Lize F D van Vulpen, Wouter Foppen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 20, 2023
Monitoring recovery of joints after bleeding: Physical examination and ultrasound are complementaryFlora H P van Leeuwen, Kathelijn Fischer, Wouter Foppen, et al.
Pharmacological Research|November 29, 2016
Pathophysiology of hemophilic arthropathy and potential targets for therapyAstrid E Pulles, Simon C Mastbergen, Roger E G Schutgens, et al.
Journal of Personalized Medicine|February 23, 2024
Towards Personalized Treatment in Haemophilia: The Role of Genetic Factors in Iron and Heme Control to Identify Patients at Risk for Haemophilic ArthropathyLize F D van Vulpen, Simon C Mastbergen, Wouter Foppen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 27, 2021
On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic miceAstrid E Pulles, Lize F D van Vulpen, Katja Coeleveld, et al.
Research and Practice in Thrombosis and Haemostasis|January 24, 2025
No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapyKonrad van der Zwet, Mark Roest, Dana Huskens, et al.
Pageof 5